Amarin Seeks EU Fast-Track For Potential Cardiovascular Blockbuster
Three other companies have also requested an accelerated assessment
Amarin’s cardiovascular risk reducing drug, Vascepa, is among four new products being considered for accelerated assessment by the European Medicines Agency.
